Cellectar Biosciences reports Q2 financial results, conference call on August 14.

• Cellectar Biosciences to report Q2 2025 results on August 14, 2025. • Conference call at 8:30am Eastern Time. • Toll-free number: 1-800-717-1738. • Conference ID: 94699. • Webcast available on the company's Investor Relations website.

Cellectar Biosciences (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company, has scheduled its second quarter 2025 financial results announcement and corporate update for August 14, 2025, at 8:30 AM ET. The company will host a conference call accessible via toll-free number 1-800-717-1738 (Conference ID: 94699) and webcast. A replay of the presentation will be available in the Events section of Cellectar's Investor Relations website [1].

Cellectar Biosciences focuses on the discovery, development, and commercialization of drugs for cancer treatment. The company's proprietary Phospholipid Drug Conjugate™ (PDC) delivery platform aims to develop the next generation of cancer cell-targeting treatments, delivering improved efficacy and better safety by minimizing off-target effects. Cellectar's product pipeline includes iopofosine I 131, CLR 121225, and CLR 121125, among others [1].

Investors and financial professionals are encouraged to participate in the conference call and webcast to gain insights into Cellectar's financial performance and corporate update. For more information, please visit Cellectar's Investor Relations website.

References:
[1] https://www.stocktitan.net/news/CLRB/cellectar-biosciences-to-report-second-quarter-financial-results-and-la636yqfo3tb.html